Analysis of the benefit of anti-PD-1 monotherapy according to NGS-diagnosed genetic alterations in patients with non-small cell lung cancer

Aim: Immune checkpoint inhibitors improved the survival of advanced non-small cell lung cancer. However, only 20% of patients respond to these treatments and the search for predictive biomarkers of response is still topical. The objective of this work is to analyze the anti-PD-1 monotherapy benefit...

Full description

Saved in:
Bibliographic Details
Main Authors: Hortense De Saint Basile, Reza Elaidi, Zineb Maaradji, Hélène Blons, Rym BenDhiab, Laure Gibault, Elizabeth Fabre
Format: Article
Language:English
Published: Open Exploration Publishing Inc. 2024-12-01
Series:Exploration of Targeted Anti-tumor Therapy
Subjects:
Online Access:https://www.explorationpub.com/Journals/etat/Article/1002283
Tags: Add Tag
No Tags, Be the first to tag this record!